NeurAxon, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference August 5, 2010

WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference taking place August 5, 2010 in New York City.

The NeurAxon presentation will be delivered on Thursday, August 5, 2010 at 11:15am Eastern Time at the Sheraton New York Hotel & Towers.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

About NeurAxon Inc.

NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.



CONTACT:

Corporate Communications Contact:
MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."